Trial · NCT02385760
CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris
NCT02385760, Phase 2, Completed, Celtaxsys, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris. Trials, record NCT02385760. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02385760
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris
- NCT number
- NCT02385760
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 124 participants, actual
- Lead sponsor
- Celtaxsys, Inc.
- Conditions
- Acne Vulgaris
- Interventions
- CTX-4430, Placebo
- First posted
- 2015-03-11
- Last updated
- 2016-08-02
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy as measured by inflammatory lesion counts | 12 weeks | Change from baseline in inflammatory lesion count after 12 weeks of treatment as compared to placebo. |
| Primary | Safety as measured by the incidence of treatment emergent adverse events | 12 weeks | Incidence of treatment emergent adverse events as compared to placebo. |
| Secondary | Efficacy as measured by Investigator Global Assessment (IGA) | 12 weeks | The proportion of participants achieving Grade 0 or 1 with a two grade improvement in the IGA from baseline to the end of the 12 weeks of treatment as compared to placebo. |
| Secondary | Efficacy as measured by non-inflammatory lesion counts | 12 weeks | Change from baseline in non-inflammatory lesion counts after 12 weeks of treatment as compared to placebo. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02385760
GET https://conductscience.org/api/trials/v1/NCT02385760/registered